MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
AbbVie General and Administrative Expenses 2011-2025 | ABBV
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses AbbVie
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.8 B | 12.9 B | 15.3 B | 12.3 B | 11.3 B | 6.94 B | 7.4 B | 6.28 B | 5.86 B | 6.39 B | 7.72 B | 5.35 B | 4.99 B | 5.89 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.3 B | 4.99 B | 8.81 B |
Quarterly General and Administrative Expenses AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.57 B | 3.25 B | 3.29 B | 4.2 B | 3.38 B | 3.32 B | 3.37 B | 3.27 B | 3.04 B | - | 3.3 B | 5.41 B | 3.13 B | - | 3.08 B | 3.16 B | 2.84 B | - | 2.85 B | 3.53 B | 1.7 B | - | 1.66 B | 1.65 B | 1.68 B | - | 1.92 B | 1.76 B | 1.79 B | - | 1.46 B | 1.51 B | 1.37 B | - | 1.38 B | 1.47 B | 1.36 B | - | 1.47 B | 1.7 B | 1.47 B | - | 1.6 B | 1.45 B | 1.34 B | - | 1.26 B | 1.41 B | 1.24 B | - | 1.08 B | 1.25 B | 1.25 B | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.41 B | 1.08 B | 2.27 B |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.8 | 0.18 % | $ 797 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
22.2 M | $ 2.99 | -1.64 % | $ 231 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 1.16 | -0.85 % | $ 6.33 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 212.82 | - | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
10.2 M | $ 0.65 | -30.61 % | $ 179 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 2.9 | -6.3 % | $ 6.98 B |  Australia |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
8.57 M | $ 1.24 | -2.36 % | $ 1.83 M | USA |
 |
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 94.54 | -0.52 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
56.7 M | $ 26.68 | -0.48 % | $ 1.29 B | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
95.8 M | $ 9.49 | 0.05 % | $ 139 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 0.26 | 46.74 % | $ 566 M |  Israel |
 |
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
741 M | $ 583.06 | -1.37 % | $ 44.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.42 | -4.35 % | $ 15.2 M | USA |
 |
AstraZeneca PLC
AZN
|
15.2 B | $ 92.42 | -0.03 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
14.7 M | $ 12.4 | 0.24 % | $ 816 M | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 9.05 | 0.5 % | $ 1.48 B | Britain |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 10.62 | -1.71 % | $ 687 M | USA |
 |
Biogen
BIIB
|
2.4 B | $ 175.85 | -0.27 % | $ 25.6 B | USA |
|
Cerevel Therapeutics Holdings
CERE
|
113 M | - | - | $ 7.29 B | USA |
 |
Abeona Therapeutics
ABEO
|
19 M | $ 5.4 | -0.16 % | $ 115 M | USA |
 |
Celldex Therapeutics
CLDX
|
38.5 M | $ 26.05 | -2.91 % | $ 1.68 M | USA |